Most of the peptide weight-management drugs covered on this site work through the GLP-1 receptor, alone or paired with GIP or glucagon receptors. Cagrilintide takes a different route: it targets amylin, a separate appetite-regulating hormone entirely, and its combination with semaglutide, known as CagriSema, is one of the most closely watched candidates currently in front of the FDA.
What Amylin Does
Amylin is a hormone co-secreted with insulin by the pancreas after eating. Its natural roles include slowing gastric emptying, promoting a feeling of fullness, and suppressing glucagon, effects that overlap with, but are mechanistically distinct from, what GLP-1 does. Because amylin signaling operates through its own separate receptor pathway, combining an amylin analog with a GLP-1 drug is a plausible way to layer two complementary appetite and satiety mechanisms rather than simply increasing the dose of one.
What Cagrilintide Is
Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk, engineered similarly to how semaglutide extended the natural GLP-1 hormone's half-life, allowing once-weekly dosing instead of the much more frequent dosing natural amylin signaling would require. On its own, cagrilintide has been studied as a weight-management candidate, but its most advanced and widely discussed use is in fixed-dose combination with semaglutide.
What CagriSema Is and What the Trials Showed
CagriSema combines cagrilintide and semaglutide, both at 2.4 mg, in a single once-weekly injection. In the Phase 3 REDEFINE 1 trial, which enrolled more than 3,400 participants, those who completed treatment lost an average of approximately 20.4% of their body weight, compared with 3.0% in the placebo group; in an analysis estimating the effect if everyone had stayed on treatment as intended, the figure rose to roughly 22.7%. Nearly 92% of participants on CagriSema achieved at least 5% weight loss, compared with about 31.5% on placebo.
Regulatory Status
Novo Nordisk submitted a New Drug Application for CagriSema to the FDA on December 18, 2025, and the agency's review was expected to continue through 2026. As of this writing, CagriSema is not FDA-approved and is not available by prescription; it exists only within the clinical trial and regulatory review process. Any product sold outside that process under a similar name is not the reviewed formulation and carries none of its trial-backed data.
Why the Combination Approach Matters
CagriSema is being watched closely partly because it represents a genuinely different strategy than simply developing a stronger single-receptor drug: it's a bet that combining two distinct appetite-regulating pathways, GLP-1 and amylin, produces effects that neither achieves as well alone. If approved, it would be positioned as a rival to retatrutide and tirzepatide in the increasingly competitive obesity-drug landscape.
The Bottom Line
Cagrilintide and CagriSema illustrate that GLP-1 receptor agonism is not the only hormonal pathway drugmakers are pursuing for weight management, and the amylin-pathway data so far is substantial enough that regulators are actively reviewing it. Because CagriSema remains unapproved, anyone interested in it should track its regulatory status through legitimate channels and discuss currently available, FDA-approved options with a physician rather than seeking out unregulated versions.